GLP-1 agonists are contraindicated in pregnancy and breastfeeding
Max Denning, one of Eli Lilly's senior medical directors
There are also a few cautions the FDA notes specific to this drug, including but not limited to: risk of pancreatitis hypoglycemia (low blood sugar) when used in conjunction with certain other drugs renal impairment or kidney failure acute gallbladder disease increased risk of thyroid C-cell tumors The FDA notes that patients who have had, or have family members who have had, medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use liraglutide, nor should individuals who have experienced prior serious hypersensitivity reaction to the drug
The 0.4 mg difference reflects the dose found optimal for weight loss in the STEP trials vs the dose found optimal for glycemic control in the SUSTAIN trials
Clinical trials show 15-21% body weight loss depending on the medication and dose
In preclinical and in vitro studies, DSIP is being researched in relation to sleep regulation, stress resilience and pain perception, and additionally to possible antioxidant and immunomodulatory properties